Biotech Stocks Reviews
- La Jolla Rallying After Chairman Tang Bets Additonal $17M in Turnaround
Tue, Jan 14
La Jolla has been on a tear in the new year and since we first covered the name in early December at a · more » - This Company May Benefit From A Shift in Alzheimer’s Strategy
Tue, Jan 14
Stakeholders in Alzheimer’s Disease have been fixated on the amyloid thesis, which has resulted in · more » - Amarin: And Then There Was One…. Acasti and AstraZeneca Fish Oils Fail
Mon, Jan 13
Acasti reported that their first Phase 3 trial of Capre did not reach statistical significance due to an · more » - La Jolla’s 2019 Preliminary Giapreza Sales Attracting Attention
Thu, Jan 9
La Jolla (LJPC) announced preliminary Giapreza sales for 2019. The stock has traded up about 35% today · more » - The 2020 Biotechs To Keep an Eye On
Wed, Jan 1
Below we’ve outlined our watchlist with 3 main names that we think will outperform in the new year. · more » - Thesis for Existing Healthcare Names Heading into 2020
Fri, Dec 27
Thesis/Strategy For Existing Names Fennec (FENC) Read historical Fennec analysis here Fennec is · more » - FDA Grants Amarin’s Vascepa Better Than Expected Label
Sat, Dec 14
This afternoon, the FDA approved an expanded label for Vascepa to include patients who have: established · more » - Commercial Giapreza Makes La Jolla A Contrarian Play
Mon, Dec 9
La Jolla Pharma (LJPC) is a beat up contrarian play that has dropped roughly 70% since September. Why? · more » - Affimed Timeline Pushed Back, But Thesis Remains Unchanged
Wed, Nov 20
Affimed (AFMD) had a call discussing Q3 results this morning. We were looking to see if anything had · more »